Milestone Pharmaceuticals Inc. (MIST)
NasdaqGS · USD · Healthcare · Biotechnology
$0.6785 (+5.29%) as of
Key statistics
- Market cap
- 84.47M
- Forward P/E
- -0.87
- EPS (TTM)
- -0.6800
- Dividend yield
- 0.00%
- 52-week range
- 0.6310 – 3.0600
- Beta
- 1.01
- Revenue (TTM)
- 2.34M
- Profit margin
- 0.00%
- Analyst target
- $5.57
- Volume
- 389.46k
About Milestone Pharmaceuticals Inc.
Milestone Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of cardiovascular medicines in the United States and Canada. It offers CARDAMYST (etripamil) nasal spray, a prescription medication for the conversion of acute symptomatic episodes of paroxysmal supraventricular tachycardia (PSVT) to sinus rhythm in adults. The company is also developing etripamil for the indication of atrial fibrillation with rapid ventricular rate (AFib-RVR). It has a license and collaboration agreement with Corxel Pharmaceuticals to develop and commercialize etripamil. Milestone Pharmaceuticals Inc.was incorporated in 2003 and is headquartered in Montreal, Canada.
- Sector
- Healthcare
- Industry
- Biotechnology
- Headquarters
- Montreal, QC, Canada
- Employees
- 38
Financial statements (income statement, balance sheet, cash flow) and an interactive price chart are available on this page with JavaScript enabled.